Description
KEYNOTE-048 supports pembrolizumab alone or in combination with chemotherapy as standard first-line therapies for recurrent/metastatic head and neck cancer
Article: KEYNOTE-048 supports pembrolizumab alone or in combination with chemotherapy as standard first-line therapies for recurrent/metastatic head and neck cancer
€3.03
Reviews
There are no reviews yet.